Citadel Advisors LLC grew its holdings in Galapagos NV (NASDAQ:GLPG) by 27.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,179 shares of the biotechnology company’s stock after buying an additional 3,024 shares during the period. Citadel Advisors LLC’s holdings in Galapagos were worth $1,443,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in GLPG. Advisors Preferred LLC acquired a new stake in shares of Galapagos in the third quarter valued at approximately $105,000. New York State Common Retirement Fund acquired a new stake in shares of Galapagos in the second quarter valued at approximately $166,000. Acadian Asset Management LLC acquired a new stake in Galapagos during the 2nd quarter worth approximately $166,000. Pacad Investment Ltd. acquired a new stake in Galapagos during the 2nd quarter worth approximately $168,000. Finally, Trexquant Investment LP acquired a new stake in Galapagos during the 2nd quarter worth approximately $214,000. 19.71% of the stock is owned by institutional investors.
Several analysts recently weighed in on GLPG shares. Stifel Nicolaus lifted their price target on Galapagos from $101.00 to $120.00 and gave the stock a “buy” rating in a report on Friday, September 15th. Nomura lifted their price target on Galapagos from $108.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, August 11th. Cowen reissued a “buy” rating on shares of Galapagos in a report on Thursday, August 10th. BTIG Research reissued a “buy” rating and set a $118.00 price target on shares of Galapagos in a report on Monday, November 20th. Finally, Zacks Investment Research raised Galapagos from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $111.00.
ILLEGAL ACTIVITY WARNING: This story was published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3079022/citadel-advisors-llc-has-1-44-million-holdings-in-galapagos-nv-glpg.html.
Galapagos Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.